Day Return
YTD Return
1-Year Return
3-Year Return
5-Year Return
Note: Sector performance is calculated based on the previous closing price of all sector constituents
Industries in This Sector
Select an Industry for a Visual Breakdown
Industry | Market Weight | YTD Return | |
---|---|---|---|
All Industries | 100.00% | 3.88% | |
Drug Manufacturers - General | 33.97% | 9.26% | |
Healthcare Plans | 13.31% | -3.68% | |
Medical Devices | 12.77% | 4.42% | |
Diagnostics & Research | 11.66% | 6.00% | |
Biotechnology | 11.30% | -4.36% | |
Medical Instruments & Supplies | 6.62% | 3.83% | |
Medical Care Facilities | 2.97% | 13.99% | |
Drug Manufacturers - Specialty & Generic | 2.76% | -4.25% | |
Medical Distribution | 2.36% | 9.50% | |
Health Information Services | 2.06% | 5.21% | |
Pharmaceutical Retailers | 0.23% | -33.77% |
Note: Percentage % data on heatmap indicates Day Return
All Industries
-
Largest Companies in This Sector
Name | Last Price | 1Y Target Est. | Market Weight | Market Cap | Day Change % | YTD Return | Avg. Analyst Rating |
---|---|---|---|---|---|---|---|
760.00 | 856.61 | 11.19% | Buy | ||||
512.81 | 566.61 | 7.31% | Buy | ||||
149.91 | 172.72 | 5.59% | Buy | ||||
130.06 | 141.42 | 5.10% | Buy | ||||
160.75 | 182.41 | 4.40% | Buy | ||||
593.03 | 622.29 | 3.51% | Buy | ||||
253.38 | 271.39 | 2.91% | Buy | ||||
104.74 | 126.23 | 2.82% | Buy | ||||
310.15 | 316.41 | 2.58% | Buy | ||||
28.01 | 31.37 | 2.46% | Buy |
Investing in the Healthcare Sector
Start Investing in the Healthcare Sector Through These ETFs and Mutual Funds
ETF Opportunities
Name | Last Price | Net Assets | Expense Ratio | YTD Return |
---|---|---|---|---|
143.59 | 37.936B | 0.09% | ||
262.19 | 20.002B | 0.10% | ||
133.40 | 6.991B | 0.45% | ||
88.14 | 6.358B | 0.35% | ||
55.83 | 5.241B | 0.40% |
Mutual Fund Opportunities
Name | Last Price | Net Assets | Expense Ratio | YTD Return |
---|---|---|---|---|
212.95 | 45.706B | 0.29% | ||
89.79 | 45.706B | 0.29% | ||
131.21 | 20.002B | 0.10% | ||
92.43 | 14.712B | 0.80% | ||
92.16 | 14.487B | 0.80% |
Healthcare Research
Discover the Latest Analyst and Technical Research for This Sector
Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We Cover
In this edition, we assess exposure of some consumer finance banks; Compass Minerals puts its dividend on ice; Humana's stock pitch shows a rare opportunity; and Enel SpA, Warner Bros. Discovery, and Puma.
Analyst Report: HCA Healthcare, Inc.
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the United States. As of December 2022, the firm owned and operated 182 hospitals, 126 freestanding outpatient surgery centers, and a broad network of physician offices, urgent-care clinics, and freestanding emergency rooms across 20 states and a small foothold in England.
RatingPrice TargetAnalyst Report: Guardant Health, Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
RatingPrice TargetAnalyst Report: Mettler-Toledo International Inc.
Mettler-Toledo supplies weighing and precision instruments to customers in the life sciences, industrial, and food retail industries. Its products include laboratory and retail scales, pipettes, pH meters, thermal analysis equipment, titrators, metal detectors, and X-ray analyzers. Mettler leads the market for weighing instrumentation and controls more than 50% of the market for lab balances. The business is geographically diversified, with sales distribution roughly as follows: United States around 30% of sales, Europe around 30%, China around 20%, and the rest of the world around 20%.
RatingPrice Target